IMA is loading

The production of minitablets for the sustained release of a drug is a promising area in pharmaceutical research.

Directly compressed minitablets coated in a solid wall pan for the sustained release of drugs.

Introduction

The production of minitablets for the sustained release of a drug is a promising area in pharmaceutical research.
Minitablets are multiple unit dosage forms, therefore they present all the advantages of these systems over the single unit dosage forms such as low risk of dose dumping, high degree of dispersion in the GI tract and reproducible bioavailability. Moreover, if they are manufactured by direct compression instead of granulation or extrusion and spheronization, the production is one step and leads to lower costs and higher production yields. [1, 2] Sustained release minitablets can be produced either as matrix or by coating the minitablets in a fluid bed apparatus. [3] Until now the coating of minitablets in a pan has not been extensively utilised; [4] however this process shows advantages over the fluid bed providing higher production capabilities, lower waste of coating materials and faster equipment cleaning time.

 

Aim of the study

The aim of this research was to investigate the possibility of manufacturing a sustained release multiple dosage form by coating in a solid wall pan minitablets produced by direct compression; theophylline was employed as a model drug and WAS, an innovative ready to use pigment dispersion, was tested to evaluate the possibility of reducing production time.

 

Materials

Theophylline (TH, particle lower than 100 microns) was purchased from BASF (Ludwigshafen, Germany). Avicel PH 102 was kindly supplied by FMC Biopolymer (Brussels, Belgium). Spray dried lactose, magnesium stearate, talc, titanium dioxide, trietilcitrate and Yellow Quinoline (all FU grade) were purchased from Polichimica, (Bologna Italy) and used as received. Eudragit RL, Eudragit RS (polymer conforms to ‘Ammonio Methacrylate Copolymer, Type A’ USP/NF 31) and WAS (containing talc, Titanium dioxide, Yellow Quinoline and Trietilcitrate) were kindly supplied by Rofarma Italia (Milano Italy).

 

Methods

TH, Avicel PH 102, lactose spray dried and magnesium stearate (total 4 kg per batch) were blended using an IMA Cyclops blender. Direct compression was performed using a tablet press machine for R&D and small batches, IMA Prexima 80, equipped with 2 EU-D punches fitting 24 mini-punches, 2 mm diameter each.
Compression force used to obtain 9 mg minitablets was maintained at 20 kN for all batches with die feeder speed adjusted to 25 rpm.

 

Coating of minitablets

Coating process of 10 kg minitablets for each batch was performed in an IMA GS 25 L solid wall pan.
Two different coating formulae were used (Table 1): a traditional one containing single components to be previously dispersed in water (A) and the ready to use pigment dispersion WAS (B).
Both formulae were tested at different polymer amounts expressed in total solids weight gain percentage. Process parameters for formula A and B are described in Table 2.

 

Ingredient A B
Eudragit RS/RL 30D 4.47/6.69 4.45/6.66
Trietilcitrate 2.23 2.22
Talc 5.58
Titanium Dioxide 0.70
Yellow Quinoline 0.33
WAS 6.67
Water 80.00 80.00

Table 1: coating formula A and B in percentages.

 

Parameter Unit Value (A) Value (B)
Process time min 260 270
Inlet air temperature °C 61 59-61
Outlet air temperature °C 39 39.5
Inlet air quantity m3/h 240 250
Negative pressure mmcw -2 -2
Cores temperature °C 33 34
Spray rate ml/min 35 35
Pan speed rpm 22 22
Spray pressure bar 1.5 1.5
Nozzle diameter mm 1.4 1.4
Air Cap (one gun) 1 1

Table 2: parameters used for minitablet film coating.

 

Characterisation

The minitablets (mT) were tested for uniformity of mass, friability and crushing strength and the surface characteristics were observed by Scanning Electron Microscopy (SEM ESEM-FEI Quanta 200). The coated minitablets (CmT) were characterized with regards to the actual drug content and in vitro drug release profiles (USP paddle method, 50 rpm, 900 ml pH 7.4 phosphate buffer at 37 °C). The analysis was performed spectrophotometrically (UV2, Unicam) at 271.8 nm.

 

Result and discussion

In the first part of the study, four batches of minitablets containing different amounts of the drug (Table 3) were producted to select the formulation which had satisfactory mechanical properties to enable their coating in a pan, minimal weight variation and maximum drug content. All the minitablets produced had suitable technological properties for the coating (high crushing strength and very low friability) and complied with the test for uniformity of mass, according to European Pharmacopoeia. Batch mT4 was then selected for coating due to the highest drug content.
The second part of the study aimed to demonstrate the feasibility of minitablet coating in a solid wall pan and to test the possibility of replacing a standard coating preparation with a ready to use system. Comparing the operative parameters used in coating involving formula A and B (Table 2) it is evident that the coating conditions were very similar, this demonstrates the interchangeability of the traditional formula containing the single components with the ready to use pigment dispersion.

 

  Composition % Characteristics
Batch TH Excipients* Unit of mass Crushing strength (N) Friability (%)
mT 1 50 50 comply 18.7 ± 0.3 0.09
mT 2 60 40 comply 17.3 ± 0.5 0.13
mT 3 70 30 comply 16.6 ± 0.4 0.17
mT 4 80 20 comply 16.4 ± 0.5 0.10
* The mixture of excipients contains: spray-dried lactose 60%, Avicel PH 102 39%, magnesium stearate 1%.

Table 3: composition and characteristics of mT.
* The mixture of excipients contains: spray-dried lactose 60%, Avicel PH 102 39%, magnesium stearate 1%

 

The SEM photographs (Figure 1) of uncoated mT4 and coated m-T at different level show that a complete and uniform layer was achieved using both formulae even at low coating level.

 

 

Figure 1: SEM of uncoated mT4, formula A at different coating levels, formula B at different coating levels.

 

As shown in Figure 2, the uncoated mT released the 100% of active ingredients in less than 90 minutes.
A sustained release was ensured by both formulae and all polymer amounts, proportionally to the coating level. At the same coating level the dissolution profiles of both formulae were not significantly different, suggesting that the ready to use system is equivalent to the traditional one.

 

Figure 2: dissolution of uncoated and coated mT (formula A and B) at different total solids weight gain.

 

Conclusion

The results obtained showed that minitablets having a high amount of TH, low friability and high crushing strength were obtained by direct compression. A solid wall pan represents a suitable technique for minitablets coating and the use of a ready to mix pigment dispersion represents a suitable method to shorten coating suspension preparation time. Therefore a sustained release multiple dosage form was successfully manufactured by using a tablet press and a solid wall pan.

 

References

[1] Lopes, C.M.; Sousa Lobo, J. M.; Costa, P.; Pinto, J. F.; Directly compressed mini matrix tablets containing Ibuprofen: preparation and evaluation of sustained release; Drug. Dev. Ind. Pharm. (32) 95-106; 2006.
[2] Riis, T.; Bauer-Brandl, A.; Wagner, T.; Kranz, H.; pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulated extended release formulations; Eur. J. Pharm. Biopharm. (65) 78-84; 2007.
[3] Tomuta, I.; Leucuta, S. E.; The influence of formulation factors on hte kinetic release of metroprolol tartrate from prolong release coated mini tablets; Drug. Dev. Ind. Pharm. (33) 1070-1077; 2007.
[4] Spadoni, A.; Funaro, C.; Genovesi, A.; Vecchio, C.; Evaluation of an alternative dosage form to enteric coated pellets containing Ibuprofen: a case study; Pharmaceutical Processing, 52-54; 2001.

In collaboration with:

Dismissclose

Relive
Achema

The exclusive tech videos shot during Achema 2024 are now available on our dedicated website